Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir for mild COVID-19
IRCT20210914052480N2Phase 3Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir plus supportive care with Placebo plus supportive care (2 arms). Primary endpoints: PCR test result, Cycle threshold number and 9 more. Started Apr 2022; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20210914052480N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210914052480N2.